Clinical trials: SIRS(Systemic Inflammatory Response Syndrome)
- Condition SIRS(Systemic Inflammatory Response Syndrome)
- Funder type Industry (pharma, biotech, devices)
Sepsis, Septic Shock
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic…
- Trial name
- SYMON II (NCT06654895)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- Bluejay Diagnostics, Inc.
Sepsis
Dysfunctions of Human Muscle Stem Cells in Sepsis
Severe critical illness is often complicated by Intensive Care Unit - Acquired Weakness (ICU-AW), which is associated with increased in and post-ICU mortality, with delayed weaning from mechanical ventilation and with long-term…
- Trial name
- DISCUSS (NCT02789995)
- Testing
- Human biological samples
- Where
- 7 sites in France
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Sepsis, Intoxication; Septic
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.
This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of sepsis.
- Trial name
- NCT03764085
- Testing
- Rheosorbilact®, Ringer lactate
- Where
- 13 sites in Georgia, Kazakhstan and 3 more
- Volunteers
- 180 people
- Sponsor
- Yuria-Pharm
Bacteremia
T2Bacteria Panel Pivotal Study
The purpose of this study is to demonstrate the safety and effectiveness of the T2Bacteria Panel by validating the clinical performance (i.e.
- Trial name
- T2Bacteria (NCT02535468)
- Where
- 3 sites in United States
- Volunteers
- 2,430 people
- Sponsor
- T2 Biosystems
Urinary Tract Infection, Complicated, Acute Pyelonephritis
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
A multi-center, retrospective study of cases of serious bacterial infections including complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP), Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Acquired…
- Conditions
- Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02420366
- Where
- 22 sites in United States, Greece and 2 more
- Volunteers
- 257 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Candidemia, Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.
- Trial name
- NCT00802854
- Where
- 10 sites in South Korea
- Volunteers
- 244 people
- Sponsor
- Pfizer
Septic Shock
Efferon LPS Hemoperfusion for Treatment of Patients With Septic Shock
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve…
- Trial name
- NCT04884854
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Efferon JSC
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI)
- Trial name
- NCT07089186
- Testing
- Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Sepsis
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis.
- Trial name
- NCT00089986
- Testing
- Intravenous GR270773- Phospholipid Emulsion
- Where
- 390 sites in United States, Argentina and 32 more
- Volunteers
- 1,415 people
- Sponsor
- GlaxoSmithKline
Severe Sepsis
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
- Trial name
- NCT02960854
- Testing
- Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Septic Shock, Sepsis
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.
- Conditions
- Septic Shock, Sepsis, Hypovolemia
- Trial name
- VBI-S-02 (NCT06072430)
- Testing
- VBI-S
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Vivacelle Bio
Sepsis, Septic Shock
Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis
One of the major health problems in the world is sepsis, the number of cases of which, according to WHO, annually reaches 20-30 million.
- Trial name
- LASSONEO (NCT05707494)
- Testing
- Efferon LPS NEO
- Where
- 7 sites in Russia
- Volunteers
- 78 people
- Sponsor
- Efferon JSC
Sepsis
Value of Laboratory Biomarkers in Prediction of Outcome in Septic Patients
Sepsis is defined as a dysregulated host response to infection . Despite ongoing efforts, both the incidence and mortality of sepsis have demonstrated limited reductions over the past years,There are several biomarkers that have…
- Trial name
- NCT06338124
- Testing
- Triglyceride glucose index
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Egymedicalpedia
Sepsis, Severe Sepsis
Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment
The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a fluid treatment-specific…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03752489
- Testing
- Treatment-specific InSight, InSight
- Volunteers
- 51,645 people, healthy volunteers welcome
- Sponsor
- Dascena
Sepsis
Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis
The objective of this study is to demonstrate that rPAF-AH is safe and reduces 28 day all cause mortality in patients with severe sepsis.
- Trial name
- NCT00037687
- Testing
- rPAF-AH
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- ICOS Corporation
Viruria, Viremia
An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria
This study will evaluate the clinical efficacy and safety of a combination of leflunomide and orotic acid in kidney transplant patients with high levels of Polyoma BK viruria for the purpose of preventing Polyoma BK viremia and…
- Trial name
- NCT01620268
- Testing
- Leflunomide and orotic acid
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Changzheng-Cinkate
Sepsis
A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers
This compound, GR270773, is a lipid based compound being developed to treat Sepsis. Lipids are broken down in the body by the liver.
- Trial name
- NCT00158769
- Testing
- Intravenous GR270773 - Phospholipid emulsion
- Where
- Slovakia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sepsis
Discharge Readmission Analysis and Management in Sepsis (DReAMS-2)
This is an adaptive platform. This study is being done to collect information that will help us identify trends in patients with sepsis and other health conditions being readmitted into hospitals within 30 days of being…
- Trial name
- NCT06099756
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Measure Labs, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
This open-label, dose-response study will evaluate the safety and efficacy of CM4620-IE in patients with acute pancreatitis and accompanying SIRS. The study will consist of two phases.
- Trial name
- NCT03401190
- Testing
- CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- CalciMedica, Inc.
Septic Shock
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Septic shock is a potentially life-threatening condition that can result in multi-organ dysfunction syndrome (MODS) and mortality.
- Trial name
- SSAIL (NCT02317549)
- Testing
- LB1148
- Where
- 34 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Leading BioSciences, Inc